Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Leerink Partners analyst Andrew Berens initiates coverage on Immuneering (NASDAQ:IMRX) with a Outperform rating and announce...
HC Wainwright & Co. analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $11 price target.
Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today annou...
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ: IMRX) with a Buy and raises the price target from $13...
Oppenheimer analyst Jay Olson maintains Immuneering (NASDAQ: IMRX) with a Outperform and raises the price target from $21 to...
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...
